Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
Authors
Keywords
Breast cancer, Trastuzumab-emtansine, T-DM1, HER2, Exosome
Journal
BMC CANCER
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-05-02
DOI
10.1186/s12885-018-4418-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- KeepEX, a simple dilution protocol for improving extracellular vesicle yields from urine
- (2017) M. Puhka et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Extracellular vesicle isolation and characterization: toward clinical application
- (2016) Rong Xu et al. JOURNAL OF CLINICAL INVESTIGATION
- The biology and function of exosomes in cancer
- (2016) Raghu Kalluri JOURNAL OF CLINICAL INVESTIGATION
- Versatile roles of extracellular vesicles in cancer
- (2016) Nobuyoshi Kosaka et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined treatment with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes
- (2015) Ikuhiko Nakase et al. Scientific Reports
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Biogenesis and secretion of exosomes
- (2014) Joanna Kowal et al. CURRENT OPINION IN CELL BIOLOGY
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Exosome-mediated delivery of siRNA in vitro and in vivo
- (2012) Samir El-Andaloussi et al. Nature Protocols
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- Microvesicles: Messengers and mediators of tumor progression
- (2011) Khalid Al-Nedawi et al. CELL CYCLE
- Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy
- (2011) Valentina Ciravolo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes
- (2009) Josiah Ochieng et al. EXPERIMENTAL CELL RESEARCH
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started